Tuberculosis Clinical Trial
Official title:
Immunomodulatory Effect of Vitamin D Supplementation on Monocyte in Major Beta-thalassemia
Thalassemia becomes one of global health issue and so does Indonesia. In 2015, more than 7600
children were diagnosed as this hemoglobin genetic disease wherein anemia and lifetime blood
transfusion contribute to their morbidity and mortality in Indonesia. Major β-Thalassemia is
the most common type found. However, along with disease progression and age, iron
accumulation and dysregulation becomes the most common complication exist. In cellular level,
this condition results in cell and tissue damage especially immune cells and promotes favor
condition for siderophilic bacteria such as Mycobaterium tuberculosis (Mtb) to growth
rapidly. Severe infection becomes the second most cause of death in thalassemia-β major
patients.
Tuberculosis (Tb) remains the global health issue especially in developing countries. Based
on World Health Organization (WHO) report on 2015, Indonesia is the second highest burden of
TB in the world. Both of adaptive and innate immune system plays important role in Mtb
recognition and eradication. However, immune cells mechanism and activity in response to Mtb
infection during iron accumulation condition on thalassemia-β major patients may be altered
therefore need for further study. Macrophage is an adaptive immune cell, has a pivotal role
on circulating-iron regulation and serves as Mtb host cell. To understand macrophage activity
on thalassemia-β major patients can be studied by monocyte characteristic stimulated by Mtb
antigen and evaluated by its differentiation into three subsets based on CD14 and CD16. Mtb
antigen presentation is identified by HLA-DR expression on monocyte membrane.
Vitamin D is one of the most affected micronutrients on major β-thalassemia patients, yet it
has immunomodulatory effect on immune system. Recent finding of vitamin D receptor (VDR)
expressed in monocyte strongly convince that vitamin D should be maintained in major
β-thalassemia patients where it is found lower in these patients. Thus, this original and
true report aimed to declare that the research activity has finished and the data has been
elaborated. Future plan is developing the original article based on the research finding
corroborating the previous knowledge and innovative suggestion for the quality of
thalassemia.
This study was designed as a non-randomized, open label, intervention study and performed at
the thalassemia clinic of the Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
Vitamin D deficiency in the general population is common in Indonesia with a prevalence of
41% reported in one study1. Sixty children (aged 1 month to 15 years) diagnosed as major
β-thalassemia confirmed by clinical and hemoglobin electrophoresis who regularly having blood
transfusion at least once in a month controlled in the clinic, from March - May 2018 were
recruited prospectively. In addition, children who had ferritin serum >1000 µg/L in the last
three months were met criteria for enrollment. Children who had tuberculosis or co-infection
(hepatitis B, hepatitis C, and cytomegalovirus) and sign of acute infection were not eligible
for enrollment. Informed consent was obtained from parents or child's guardian. Vitamin D
levels were measured before and after supplementation while identifying their vitamin D
sufficiency status. Classification of vitamin D sufficiency were used according to The
Endocrine Society Clinical Practice Guideline, which stated that the level of 25(OH)D of < 20
ng/ml was considered to be vitamin D deficiency whereas a 25(OH)D of 21-29 ng/ml was
considered to be insufficient. Then, a sufficient vitamin D was considered when the
concentration of 25(OH)D was 30 ng/mL or above.2 No healthy control was enrolled to test for
variability in the laboratory tests over time in this study.
The intervention provided according to the participants' state of vitamin D sufficiency.
vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU
cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while
those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance
was systematically monitored using drug monitoring diary evaluated by researchers. Blood
samples for the study objectives were taken at enrollment and after eight weeks of
cholecalciferol supplementation during routinely scheduled visits to the clinic. The outcome
measure was the change in the proportion of monocyte subsets and the expression of
membrane-bound protein of monocyte consist of CD14, CD16, and HLA-DR.
All procedures were conducted in accordance with policies of the Faculty of Medicine,
Universitas Padjadjaran and Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
This study was approved by Health Research Ethics Committee of Medical Faculty Universitas
Padjadjaran Bandung with approval number 50/UN6.KEP/EC/2018. All participants signed a
written informed consent. All participants signed a written informed consent. This study was
registered in clinicaltrial.gov
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |